NEK7 protein (NIMA-related kinase 7) is a 34 kDa serine/threonine kinase encoded by the [NEK7](/genes/nek7) gene. NEK7 is the essential structural mediator of [NLRP3](/proteins/nlrp3-protein) inflammasome assembly, directly bridging NLRP3 protomers to enable oligomerization. In the brain, NEK7-dependent inflammasome activation in [microglia](/cell-types/microglia) is a major driver of neuroinflammatory damage in [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease).
...
NEK7 Protein
Overview
NEK7 protein (NIMA-related kinase 7) is a 34 kDa serine/threonine kinase encoded by the [NEK7](/genes/nek7) gene. NEK7 is the essential structural mediator of [NLRP3](/proteins/nlrp3-protein) inflammasome assembly, directly bridging NLRP3 protomers to enable oligomerization. In the brain, NEK7-dependent inflammasome activation in [microglia](/cell-types/microglia) is a major driver of neuroinflammatory damage in [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease).
NEK7 is a relatively compact kinase consisting of:
N-terminal extension (residues 1-20): Unstructured region that contributes to protein-protein interactions
Kinase domain (residues 21-302): Bilobal kinase fold with a canonical ATP-binding pocket; the C-lobe mediates the critical interaction with [NLRP3](/proteins/nlrp3-protein)
Activation segment: Contains the conserved DFG motif and T-loop with Thr187 as the activating phosphorylation site
NLRP3 Binding Interface
The cryo-EM structure of the NEK7-NLRP3 complex (PDB: 6NPY) reveals that NEK7 contacts both the leucine-rich repeat (LRR) domain and the nucleotide-binding domain (NBD/NACHT) of NLRP3. Key interface residues include:
C-lobe of NEK7: Arg121, Glu122, Leu160, and Arg163 form hydrogen bonds with NLRP3 LRR
Back of the kinase domain: Additional contacts with the NLRP3 NACHT domain enable bridging between adjacent NLRP3 protomers
The binding interface buries approximately 2,000 Ų of surface area
Comparison with NEK6
NEK7 shares 87% kinase domain identity with [NEK6](/genes/nek6), but NEK6 cannot substitute for NEK7 in NLRP3 activation. Critical differences in the N-terminal extension and C-lobe surface residues determine NLRP3 binding specificity.
Normal Function
Mitotic Spindle Assembly
During cell division, NEK7 is phosphorylated and activated by [NEK9](/genes/nek9). The NEK9-NEK7 complex promotes:
Centrosome separation through phosphorylation of [EG5/KIF11](/genes/kif11)
Microtubule nucleation at spindle poles
Cytokinetic abscission
NLRP3 Inflammasome Assembly
In interphase cells, NEK7 is the obligate structural component for [NLRP3 inflammasome](/entities/nlrp3-inflammasome) formation:
NEK7 binds activated NLRP3 monomers in a 1:1 stoichiometry
NEK7-NLRP3 heterodimers oligomerize into a disc-shaped platform
The NLRP3 disc recruits [ASC](/proteins/asc-protein) via PYD-PYD interactions
ASC filaments recruit pro-[caspase-1](/proteins/caspase-1-protein) for auto-activation
Active caspase-1 cleaves pro-[IL-1β](/genes/il1b) and pro-[IL-18](/genes/il18) into mature cytokines
Caspase-1 also cleaves [gasdermin D](/genes/gsdmd), forming membrane pores for cytokine release
Cell Cycle Switch
NEK7 cannot simultaneously serve both mitotic and inflammasome functions. During mitosis, NEK9 sequesters NEK7 at centrosomes, preventing inflammasome activation. This switch ensures that inflammatory responses do not interfere with cell division.
Role in Disease
Alzheimer's Disease
NEK7-NLRP3 signaling is a central hub in AD neuroinflammation:
[Amyloid-beta](/proteins/amyloid-beta) fibrils phagocytosed by [microglia](/cell-types/microglia-neuroinflammation) cause lysosomal disruption, activating NEK7-NLRP3
The resulting IL-1β promotes [tau](/proteins/tau) hyperphosphorylation, creating a feed-forward loop between amyloid pathology and tauopathy
Plaque-associated microglia in AD brains show elevated NEK7 and NLRP3 co-expression
Conditional deletion of microglial Nek7 in [APP](/entities/app-protein)/PS1 mice reduces plaque burden, [tau](/proteins/tau) phosphorylation, and synaptic loss
Parkinson's Disease
Multiple PD-relevant stimuli converge on NEK7-NLRP3:
Extracellular [α-synuclein](/proteins/alpha-synuclein) aggregates trigger potassium efflux in microglia
Mitochondrial complex I deficiency increases ROS, activating NEK7-NLRP3
[LRRK2](/proteins/lrrk2-protein) G2019S gain-of-function enhances NLRP3 priming through [NF-κB](/entities/nf-kb)
[PINK1](/proteins/pink1-protein)/[Parkin](/proteins/parkin-protein) deficiency impairs mitophagy, increasing mitochondrial DAMPs that activate NEK7-NLRP3
Amyotrophic Lateral Sclerosis
[SOD1](/proteins/sod1-protein) mutant microglia show enhanced NEK7-NLRP3 complex formation. [TDP-43](/proteins/tdp-43-protein) cytoplasmic aggregates also activate NLRP3 through mitochondrial damage pathways.
Traumatic Brain Injury and Stroke
Acute neurological injuries rapidly activate NEK7-NLRP3 in microglia and infiltrating macrophages, amplifying secondary injury through IL-1β-driven neuroinflammation.
Therapeutic Targeting
Direct NEK7 Inhibition
Protein-protein interaction (PPI) disruptors: Small molecules targeting the NEK7-NLRP3 interface could selectively block inflammasome assembly without affecting NEK7 mitotic functions
Stapled peptides: Designed to mimic the NEK7 C-lobe surface and competitively inhibit NLRP3 binding
Allosteric modulators: Compounds that shift NEK7 conformation to disfavor NLRP3 interaction
Downstream NLRP3 Inhibitors
MCC950 (CRID3) blocks NLRP3 ATPase activity downstream of NEK7 and has shown efficacy in AD and PD models
Dapansutrile (OLT1177) is in clinical trials for inflammatory conditions
CY-09 and Tranilast represent additional NLRP3-targeting scaffolds
Genetic Approaches
NEK7-targeting antisense oligonucleotides (ASOs) reduce inflammasome activation in rodent models of neurodegeneration
CRISPR-mediated NEK7 disruption in iPSC-derived microglia validates the target for human disease
[He Y et al., NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux (2016) (2016)](https://doi.org/10.1038/nature16959)
[Sharif H et al., Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome (2019) (2019)](https://doi.org/10.1038/s41586-019-1295-z)
[Shi H et al., NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7 (2016) (2016)](https://doi.org/10.1038/ni.3333)
[Heneka MT et al., NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice (2013) (2013)](https://doi.org/10.1038/nature11729)
[Gordon R et al., Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice (2018) (2018)](https://doi.org/10.1126/scitranslmed.aah4066)
[Ising C et al., NLRP3 inflammasome activation drives tau pathology (2019) (2019)](https://doi.org/10.1038/s41586-019-1769-z)
[Schmid-Burgk JL et al., A genome-wide CRISPR screen identifies NEK7 as an essential component of NLRP3 inflammasome activation (2016) (2016)](https://doi.org/10.1074/jbc.C115.700492)